COCP · XBRL financial data

Cocrystal Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (COCP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	—	—	—	—	—	—	225	105
Research and development	4,194	4,267*	2,950	4,308	3,242	2,037*	1,360	1,122	954	1,619*	1,371	2,142
General and administrative	1,849	1,399*	1,208	1,140	1,800	1,193*	981	986	1,135	862*	1,210	1,147
Total operating expenses	4,443	4,666*	4,158	5,448	5,042	3,230*	2,341	2,108	2,089	2,481*	2,581	3,289
Operating income (loss)	(4,443)	(4,666)*	(4,158)	(5,448)	(5,042)	(3,230)*	(2,341)	(2,108)	(2,089)	(2,481)*	(2,356)	(3,184)
Interest expense	(320)	(180)*	(220)	(151)	(111)	(55)*	(37)	(28)	(22)	(47)*	(22)	(10)
Income tax expense (benefit)	—	—	—	—	0*	—	—	—	—	—	0	0*
Net income (loss)	(4,165)	(4,464)*	(3,956)	(5,343)	(4,939)	(3,266)*	(2,301)	(2,055)	(2,049)	(2,426)*	(2,299)	(3,164)
Earnings per share, basic USD per share	(0.41)	(0.44)*	(0.39)	(0.53)	(0.49)	(0.32)*	(0.23)	(0.20)	(0.19)	(0.18)*	(0.17)	(0.23)
Earnings per share, diluted USD per share	(0.41)	(0.44)*	(0.39)	(0.53)	(0.49)	(0.32)*	(0.23)	(0.20)	(0.19)	(0.18)*	(0.17)	(0.23)
Weighted average shares, basic thousands of shares	10,153	10,215*	10,174	10,174	10,174	10,174*	10,174	10,174	10,991	13,785*	13,786	13,788
Weighted average shares, diluted thousands of shares	10,153	10,215*	10,174	10,174	10,174	10,174*	10,174	10,174	10,991	13,785*	13,786	13,788

Fiscal quarters (COCP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	29,738	26,353	21,842	18,143	13,095	9,860	6,921	4,766	7,729	7,025	4,685	2,169
Prepaid and other current assets	1,842	1,773	1,572	365	509	430	385	282	465	328	418	256
Total current assets	32,205	29,091	24,492	19,660	14,256	11,580	8,826	6,765	8,782	8,134	5,939	3,236
Property and equipment, net	252	271	244	211	181	153	127	107	106	93	81	69
Right-of-use asset	111	1,851	1,764	1,673	1,767	1,694	1,620	1,545	1,468	1,390	1,311	1,230
Total assets	32,614	31,259	26,546	21,573	16,233	13,456	10,659	8,505	10,446	9,712	7,426	4,649
Accounts payable	568	1,222	1,234	1,743	859	1,542	808	856	745	890	1,371	1,892
Total current liabilities	1,924	3,262	2,379	2,654	1,948	2,428	1,931	1,831	1,520	2,210	2,229	2,616
Lease liability, non-current	—	1,613	1,582	1,529	1,582	1,505	1,424	1,341	1,257	1,171	1,081	989
Total liabilities	1,924	4,875	3,961	4,183	3,530	3,933	3,355	3,172	2,777	3,381	3,310	3,605
Accumulated deficit	(311,450)	(315,914)	(319,870)	(325,213)	(330,152)	(333,418)	(335,719)	(337,774)	(339,823)	(342,249)	(344,548)	(347,712)
Total stockholders' equity	30,690	26,384	22,585	17,390	12,703	9,523	7,304	5,333	7,669	6,331	4,116	1,044
Total liabilities and equity	32,614	31,259	26,546	21,573	16,233	13,456	10,659	8,505	10,446	9,712	7,426	4,649
Common shares outstanding (cover page) thousands of shares	10,174	10,174	10,174	10,174	10,174	10,174	10,174	10,259	13,784	13,786	13,787	19,263

Fiscal quarters (COCP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,165)	(4,464)*	(3,956)	(5,343)	(4,939)	(3,266)*	(2,301)	(2,055)	(2,049)	(2,426)*	(2,299)	(3,164)
Stock-based compensation	173*	158*	157	148*	253*	85*	82	84*	48*	56*	84	92*
Net cash from operating activities	(2,681)*	(3,326)*	(4,503)	(3,699)*	(5,123)*	(3,160)*	(2,939)	(2,155)*	(1,362)*	(1,736)*	(2,340)	(2,516)*
Purchases of property and equipment	0*	59*	8	0*	0*	0*	—	—	—	0*	—	—
Net cash from investing activities	0*	(59)*	(8)	0*	0*	0*	—	—	—	0*	—	—
Proceeds from issuing common stock	0*	0*	—	—	—	—	—	—	—	0*	—	—
Net cash from financing activities	0*	0*	—	—	—	—	—	—	—	1,032*	—	—
Net change in cash	(2,681)*	(3,385)*	(4,511)	(3,699)*	(5,123)*	(3,160)*	(2,939)	(2,155)*	2,963*	(704)*	(2,340)	(2,516)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.